We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Hanmi Pharmaceutical announced Friday that it will end development of the lung cancer therapy Olita (olmutinib) due to difficulties recruiting patients for pivotal studies and the cancellation of licensing deals for the third-generation tyrosine kinase in